Initial Therapeutics
Steve Sando has worked as a Scientist I in Computational Biology at Initial Therapeutics since April 2023. Prior to that, they worked as a Postdoctoral Associate at the Massachusetts Institute of Technology from September 2019 to April 2023.
Steve Sando pursued their education from 2011 to 2019 at the Massachusetts Institute of Technology, where they earned a Doctor of Philosophy (PhD) degree in Biology.
This person is not in any offices
Initial Therapeutics
Initial Therapeutics is an ATP company that develops small-molecule medicines designed to prevent pathogenic protein synthesis. The company provides an approach that is differentiated from protein degradation and other interventions that recognize and tackle proteins only after they are fully formed for medical needs.